1. Show article details.

    Alimera Sciences Announces New PDUFA Date For ILUVIEN®

    PR Newswire – 7:00 AM ET 04/14/2014

    ATLANTA, April 14, 2014 Alimera Sciences, Inc. (ALIM), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that its recent resubmission of the New Drug Application for ILUVIEN® has been acknowledged as received by the U.S. Food and Drug Administration as a complete class 2 response to the FDA's Oc...

  2. Show article details.

    Alimera makes fourth bid for eye treatment approval from FDA

    Reuters – 7:48 AM ET 03/27/2014

    Alimera Sciences Inc (ALIM) said it has applied a fourth time for U.S. regulatory approval to start selling an eye implant that delivers a drug to treat a form of blindess in diabetes patients. Alimera said it had provided a safety update and responded to questions the U.S. Food and Drug Administration raised in October, when it rejected marketing approval fo the treatment for a third time.

  3. Show article details.

    Alimera Sciences Announces Resubmission Of ILUVIEN® New Drug Application To FDA

    PR Newswire – 7:00 AM ET 03/27/2014

    ATLANTA, March 27, 2014Alimera Sciences, Inc. (ALIM), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has resubmitted its New Drug Application for ILUVIEN® to the U.S. Food and Drug Administration.

  4. Show article details.

    Alimera Sciences To Present At Cowen And Company 34th Annual Healthcare Conference

    PR Newswire – 7:30 AM ET 02/28/2014

    ATLANTA, Feb. 28, 2014 Alimera Sciences, Inc. (ALIM), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, president and chief executive officer, will present at the Cowen and Company 34th Annual Healthcare Conference on Wednesday, March 5, 2014 at 10:00 A.M. ET in Boston, MA. The pre...

  5. Show article details.

    Alimera Sciences Reports Fourth Quarter And Full Year 2013 Financial Results

    PR Newswire – 4:07 PM ET 02/27/2014

    ATLANTA, Feb. 27, 2014 Alimera Sciences, Inc. (ALIM), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the fourth quarter and full year ended December 31, 2013. "This is an exciting time for Alimera.

  6. Show article details.

    Alimera Sciences To Release Fourth Quarter And Fiscal Year 2013 Financial Results

    PR Newswire – 4:05 PM ET 02/20/2014

    ATLANTA, Feb. 20, 2014 Alimera Sciences, Inc. (ALIM), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its fourth quarter and fiscal year 2013 financial results after the market close on Thursday, February 27, 2014.

  7. Show article details.

    Alimera Sciences To Present At Citi 2014 Global Healthcare Conference

    PR Newswire – 7:30 AM ET 02/13/2014

    ATLANTA, Feb. 13, 2014 Alimera Sciences, Inc. (ALIM), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, president and chief executive officer, will present at the Citi 2014 Global Healthcare Conference on Tuesday, February 25, 2014 at 1:50 P.M. ET in New York, NY.  . The presentati...

  8. Show article details.

    Scottish Medicines Consortium Accepts ILUVIEN® For National Health Service Scotland

    PR Newswire – 9:01 AM ET 02/10/2014

    ATLANTA, Feb. 10, 2014 Alimera Sciences, Inc. (ALIM), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Scottish Medicines Consortium, after completing its assessment and review of a simple patient access scheme, has accepted ILUVIEN® for restricted use within the National Health Servic...

  9. Show article details.

    Alimera Sciences Closes $37.5 Million Private Placement

    PR Newswire – 8:20 AM ET 02/03/2014

    Alimera issued an aggregate of 6,250,000 newly-issued shares of common stock. The securities offered have not been registered under the Securities Act and may not be offered or sold in the United States without registration or an applicable exemption from the registration requirements of the Securities Act.

  10. Show article details.

    Alimera Sciences Announces $37.5 Million Private Placement

    PR Newswire – 6:45 AM ET 01/28/2014

    ATLANTA, Jan. 28, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (ALIM), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has obtained commitments from certain non-affiliated institutional investors to purchase approximately $37.5 million of its common stock in a private placement.

Page:

Today's and Upcoming Events

  • May
    8

    ALIM to announce Q1 earnings After Market (Unconfirmed)

Past Events (last 90 days)

  • Feb
    27

    ALIM Earnings Conference Call at 4:30 PM Listen

Data provided by Wall Street Horizon, Inc. © 2014

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.